ImmunoCellular Therapeutics Ltd. (IMUC) to Be Added to Russell Indexes
ImmunoCellular Therapeutics is a clinical-stage company that is developing immune-based therapies to diagnose and treat brain and other cancers. The company has begun a Phase II trial of its lead product candidate, ICT-107, which is a dendritic cell-based vaccine targeting multiple tumor-associated antigens for glioblastoma. The company announced today that it is scheduled to join the US broad market Russell 3000, Russell Global, and Russell Microcap Indexes when Russell Investments reconstitutes its comprehensive set of US and global equity indexes on June 25, 2012. This is according to a list of additions posted on June 8 on the Russell website…